Management

Dr. Wagner founded Forte, has served as Chief Executive Officer of Forte since 2018, and has served as a member of Forte’s board of directors since 2017. In 2017, Dr. Wagner was the Head of Corporate Strategy and Development at CANBridge Life Sciences. From 2014 to 2017, Dr. Wagner was the Chief Financial Officer of Pfenex Inc., a biotechnology company. From 2006 to 2014, Dr. Wagner held the positions of Director and Portfolio Manager/Sr. Equity Analyst with Allianz Global Investors, an investment manager where he was responsible for biotechnology and pharmaceutical investments. Prior to that, Dr. Wagner was the Head of Development Licensing at PDL BioPharma, a biopharmaceutical company from 2005 until 2006. Prior to PDL BioPharma, Dr. Wagner held the position of Vice President at Lehman Brothers, a financial services firm, starting in 1999 until 2005. Dr. Wagner received a B.S. from the University of Wisconsin and a Ph.D. in Chemistry from the California Institute of Technology. Dr. Wagner is also a Charted Financial Analyst (CFA) charter holder.

Mr. Riley has served as Forte’s Chief Financial Officer since March 2020. Prior to joining Forte, Mr. Riley was at Krystal Biotech, Inc., a biotechnology company, from September 2017 to February 2020 where he was the Chief Financial Officer. Previously, Mr. Riley was a founding partner since 2002 of the CFO Network LLC, a consulting firm and was Acting Chief Financial Officer at Avanex Corporation and Corporate Controller at Kosan Biosciences. He also served in numerous capacities at Troy Chemical Corporation from 1997 to 2000. Mr. Riley received a B.Sc. (Honors) from the University of Bristol (England) and an M.B.A. (Honors) from the University of Chicago, Booth School of Business. Mr. Riley is a CPA (inactive) in the state of California.

Mr. Roenfeldt joined Forte Biosciences in October 2020 and currently serves as its Chief Operating Officer. He has over 20 years of experience in clinical drug development including process development, engineering, capital construction, alliance and program management. Before joining Forte, Mr. Roenfeldt was an Alliance and Program Manager at Halozyme, overseeing multiple partnerships and development programs. Prior to that, Mr. Roenfeldt held positions of increasing responsibility and leadership at various biopharmaceutical companies, including Pfenex, Genentech, and Amgen. Mr. Roenfeldt received his B.S. in Chemical Engineering from the University of Colorado.

Mr. Ruhl joined Forte Biosciences in July 2021 and currently serves as the Chief Technical Officer. In this role, he is responsible for Forte’s technology and scientific needs and issues. He works with management to determine the short- and long-term technical requirements and investments to help the company reach its goals. He has over 35 years of experience in biopharmaceutical development and commercial manufacturing including technical roles with commercializing first in class products and commercial technology transfers associated with large capital projects. Before joining Forte, Mr. Ruhl supported a direct phase 3 transfer of a COVID warp speed monoclonal antibody downstream process at ThermoFisher, contributing to an accelerated PPQ campaign readiness with an external partnership and third-party sending site. Prior to that, Mr. Ruhl held positions of increasing responsibility and leadership at various biopharmaceutical companies, including IDEC Pharmaceuticals as Technical and Commercial Supply Director and Amgen as Commercial Drug Product Executive Director and Amgen Ireland Site Process Development Head. Mr. Ruhl received his B.Sc. in Microbiology and Chemistry from Brigham Young University.

Dr. Finck is currently serving as Forte's Senior Medical Clinician. Previously, Dr. Finck served as the acting Chief Medical Officer, Inc. of Coherus BioSciences since August 2019 and prior to that served as Coherus’s Chief Clinical Advisor from January 2019 to August 2019 and Chief Medical Officer from July 2012 to December 2018. Dr. Finck previously served as Senior Vice President and Chief Medical Officer of NKT Therapeutics Inc., a biopharmaceutical company, from September 2010 to July 2012. Prior to that, from June 2007 to June 2010, Dr. Finck served as Senior Vice President of Research and Development and Chief Medical Officer at Osprey Pharmaceuticals U.S.A., Inc., a biopharmaceutical company. Prior to that, Dr. Finck served as an executive for various biopharmaceutical companies. Dr. Finck has served as a member of the board of directors of Reform Biologics, a private biomedical technology company, since March 2021. Dr. Finck has a B.S. in Physiological Psychology from the University of California, Santa Barbara and received her M.D. and post-doctorate training in internal medicine and rheumatology from the University of California, San Francisco School of Medicine. Dr. Finck is board certified in internal medicine.